



Company Overview

Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is under study as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers.

Humanigen, Inc.

1000 Marina Boulevard
Suite 250
Brisbane, CA 94005

Humanigen Appoints Rainer Boehm, M.D., to Board of Directors

Feb 7 2018, 7:00 AM EST

Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences

Jan 25 2018, 8:00 AM EST

Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity

Dec 21 2017, 4:45 PM EST

Stock Overview

Symbol	HGEN
Exchange	OTCQB
Shares OS	14,986,712
Market Cap	\$8.99M
Last Price	\$0.60
52-Week Range	\$0.125 - \$3.00

Investor Relations

MZ Group
Mike Cole
T: 949-259-4988
mike.cole@mzgroup.us

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.